Drug Discovery World

MAY 1, 2024

UBS China healthcare analyst Chen Chen said the price increase was due to “booming investment” in drug discovery in the first two years of the Covid-19 pandemic as a result of efforts to develop vaccines. However, data from Statista predict a recovery in 2024, with the value of the Chinese pharmaceuticals sector increasing from $110.77

Vaccine 130

Vaccine Pharmaceuticals Drug Development Research 130

Drug Discovery World

MARCH 13, 2024

According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1. Singapore is among a few countries worldwide whose pharmaceutical export value far exceed the import value. UK-based molecular diagnostics group Yourgene operates in Singapore.

Government 173

Government Science Pharmaceuticals Vaccine 173

Drug Discovery World

AUGUST 8, 2023

In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1. Similarly, The Times of India says that branded generic medicines have “long fuelled India’s pharmaceutical exports” 4.

Research 130

Research Pharmacy Pharmaceuticals Government 130

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. • Anthrax Vaccines. Adjusted Net Income (1).

Government 52

Government Vaccine Production Licensing 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. covered insulin product or vaccine). state pharmaceutical assistance programs). Sunsetting of Coverage Gap Discount Program: The 70% coverage gap discount under the CGDP will continue until December 31, 2024.

Compliance 105

Compliance Pharmacy Drugs Licensing 105

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52